



Psoriatic Arthritis (US)

OVERVIEW

The US Psoriatic Arthritis (PsA) market has been experiencing large-scale change as rheumatologists continue adoption of alternate MOA biologics. Uptake of BMS' Ocrencia, Eli Lilly's Taltz, Janssen's Simponi Aria, and Pfizer's Xeljanz will challenge the current paradigm, with substantial 2018 changes anticipated.

The **RealTime Dynamix™: Psoriatic Arthritis (US)** report series provides a detailed and timely look at current and future trends in the PsA market and the effects of the future shifting landscape. The quarterly releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues updated quarterly. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the rheumatology market make this an essential tool for companies competing in the space, as well as those with near-term plans to enter it.

SAMPLE & METHODOLOGY

The report is based on an online survey of ~100 US rheumatologists and is fielded on a quarterly basis. Respondents are recruited from the Spherix Network, a proprietary group of rheumatologists in clinical practice meeting quality screening criteria. Our relationship with this network leads to more engaged respondents resulting in higher quality output.

KEY QUESTIONS ANSWERED

- What are the adoption and share trends for Simponi Aria, Ocrencia, Taltz, and Xeljanz?
- How is Otezla holding ground against the increasingly competitive biologics and the entrance of Xeljanz?
- Do rheumatologists differentiate among TNF inhibitors and if so, how?
- How will the introduction of Ocrencia impact TNF cycling and the newer alternate biologics in PsA?
- How has the launch of Taltz impacted the PsA market and Cosentyx use in particular?
- Will Taltz expand IL-17 segment or dampen Cosentyx growth?
- Will rheumatologists follow in the footsteps of dermatologists for the adoption of Taltz?
- Will the lack of PsO indication limit use of BMS' Ocrencia, Janssen's Simponi Aria, and Pfizer's Xeljanz in PsA?
- What role are patients and payers playing in the biologic brand choice?
- How closely will rheumatologist's use of Xeljanz in PsA mirror use in RA?
- What are the key barriers for uptake of the newly launched products?
- What promotional tactics are being employed for the newly launched products?

Products Profiled

Commercial Products

AbbVie (Humira), Amgen (Enbrel), BMS (Ocrencia), Celltrion/Pfizer (Inflectra), Celgene (Otezla), Eli Lilly (Taltz), Janssen (Remicade, Simponi, Stelara), Novartis (Cosentyx), Pfizer (Xeljanz), UCB Pharma (Cimzia)

Pipeline Agents

AbbVie (upadacitinib), Janssen (Tremfya)

Key Dates

- Q1 March
- Q2 June
- Q3 September
- Q4 December

Note: a three day embargo is placed on delivery to non-manufacturers allowing clients time to digest the findings before public dissemination

Deliverables

- PowerPoint report
- Frequency tables & summary statistics
- On-site or web-based presentation
- Proprietary questions (for purchasers of the annual series)
- Analyst support

Related Reports

- *RealWorld Dynamix™: Biologic/JAK/ Otezla Switching in Psoriatic Arthritis US*
- *RealTime Dynamix™: Psoriasis US*
- *RealWorld Dynamix™: Biologic/Otezla New Starts in Psoriasis US*
- *RealTime Dynamix™: Rheumatoid Arthritis US*
- *RealTime Dynamix™: Rheumatoid Arthritis EU*